This is a common, documented pharmacological effect known as a "flush." It happens because Ipamorelin triggers an acute, massive release of growth hormone
Potential considerations include: Theoretical concern about promoting angiogenesis in existing tumors (not demonstrated but mechanistically plausible) Possible interactions with dopaminergic medications Limited human safety data due to absence of completed clinical trials GHK-Cu Side Effects# GHK-Cu has an established safety profile, particularly for topical use: Topical formulations are generally well-tolerated with low irritation potential Allergic reactions are rare but possible, particularly in individuals with copper sensitivity Injection site reactions (redness, swelling) can occur with subcutaneous administration No significant systemic side effects reported at standard research doses The extensive commercial use of GHK-Cu in cosmetic products provides a broader real-world safety dataset compared to BPC-157
We do not manufacture, prescribe, or dispense medication
Lyophilised compounds are materials that have undergone: Freeze-Drying (Lyophilisation) This process removes water from the peptide under low temperature and vacuum conditions, helping preserve molecular integrity and improve long-term stability
This peptide is not an approved natural health product
Limited Clinical Safety Data : The human safety profile remains unclear because the evidence is primarily based on animal and laboratory studies rather than large-scale clinical trials
